Dianthus Therapeutics, Inc. DNTH
83.98 USD +1.28 (+1.54%)
Nov 4, 2026, 11:47 AM EST
82.21 Day range 85.92
32.42 52-week range 117.88
- YTD
- +103.78%
- 1 year
- +152.94%
- Market cap
- 4.70B
- Revenue (ttm)
- 1.90M
- EPS (ttm)
- -4.24
- Shares out
- 55.93M
- Forward P/E
- -17.94
- YTD return
- +103.78%
- 1-year return
- +152.94%
- Volume
- 310.98K
- Avg volume
- 827.16K
- Open
- 85.92
- Previous close
- 82.70
- Day's range
- 82.21 – 85.92
- 52-week range
- 32.42 – 117.88
- Beta
- 0.26
- Analysts
- Strong Buy
- Price target
- 139.06 (+65.6%)
- Earnings date
- Nov 5, 2026
5D -0.10 (-0.12%)
Key statistics
- Enterprise value
- 3.72B
- PEG ratio
- 0.00
- Price / sales
- 2429.50
- Price / book
- 3.87
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 294.30%
- Free cash flow
- -92.21M
- Total cash
- 886.81M
- Total debt
- 1.29M
- Return on equity
- -26.06%
- Short % of float
- 18.43%
- 50-day average
- 92.18
- 200-day average
- 85.22
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 139.06 +65.6% upside
Now 83.98
- Target (low)
- 113.00
- Target (mean)
- 139.06
- Target (high)
- 200.00
Ratings (0m) 18 18 buy · 0 hold · 0 sell
- Strong buy1
- Buy17
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.94865.
Financials — quick view
DNTH Revenue — quarterly 761.00K
DNTH Net income — quarterly -50.22M
DNTH EPS — quarterly -0.90
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.94454 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | -0.84628 | -0.90 | -0.05 | -6.35% |
| May 5, 2026 | Mar 31, 2026 | -1.17 | -0.85 | +0.32 | +27.35% |
| Mar 9, 2026 | Dec 31, 2025 | -0.98 | -1.43 | -0.45 | -45.92% |
| Nov 5, 2025 | Sep 30, 2025 | -0.86 | -0.97 | -0.11 | -12.79% |
| Aug 7, 2025 | Jun 30, 2025 | -0.86 | -0.88 | -0.02 | -2.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 27, 2026 | Roth Capital | init | — | Buy |
| Oct 15, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 11, 2026 | JP Morgan | init | — | Overweight |
| Sep 4, 2026 | Citigroup | init | — | Buy |
| Aug 6, 2026 | Truist Securities | main | Buy | Buy |
| Aug 6, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- dianthustx.com
News
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
Dianthus Therapeutics to Participate in Five Investor Conferences During November 
This PPL Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday 
Roth Capital Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $113 
HC Wainwright & Co. Reiterates Buy on Dianthus Therapeutics, Maintains $158 Price Target 
Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharma 
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter 
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting 
This Shopify Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Your note
Sign in to keep a note on DNTH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARR EDWARD | Officer | Sale | Mar 11, 2026 | 0 |
| GARCIA MARINO | Chief Executive Officer | Sale | Aug 6, 2026 | 65,292 |
| MCGEORGE ANNE | Director | Sale | Aug 9, 2026 | 0 |
| RANDHAWA SIMRAT | Officer | Sale | Aug 31, 2026 | 4,000 |
| READ SIMON J. | Director | Sale | Aug 18, 2026 | 0 |
| SAVITZ RYAN | Chief Financial Officer | Sale | Jul 8, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.96% | 8,199,893 | 678.13M | Jun 29, 2026 |
| Blackrock Inc. | 7.53% | 4,123,822 | 341.04M | Jun 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 7.10% | 3,888,456 | 321.58M | Jun 29, 2026 |
| Wellington Management Group, LLP | 5.89% | 3,229,882 | 267.11M | Jun 29, 2026 |
| Fairmount Funds Management LLC | 4.63% | 2,537,191 | 209.83M | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 4.59% | 2,514,946 | 207.99M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.01% | 1,649,920 | 136.45M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.91% | 1,592,149 | 131.67M | Aug 30, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 2.74% | 1,503,955 | 124.38M | Jul 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.52% | 1,380,523 | 114.17M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.23% | 1,224,305 | 101.25M | Sep 29, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 2.11% | 1,155,511 | 95.56M | Jun 29, 2026 |